Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials

Author: Benzinga Newsdesk | March 25, 2024 09:14am
  • An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.
  • The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification.
    • Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program.

Posted In: SAVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist